Clinicopathological and p53 Gene Alteration Comparison between Young and Older Patients with Gastric Cancer

Karim, Sajjad

doi:10.7314/apjcp.2014.15.3.1375

Cited by 16 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The postresection survival of EOGC patients remains elusive. 56 In our study, the 5-year survival rate in EOGC patients was 64%, which is much higher than that reported by Korean and Japanese investigators. 9 , 35 The discrepancy may be related to several factors.…”

Section: Discussioncontrasting

confidence: 59%

Gastric Carcinomas in Young (Younger than 40 Years) Chinese Patients

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 59%

Gastric Carcinomas in Young (Younger than 40 Years) Chinese Patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…p53 is one of the most important genes that are mutated in gastric cancer . In accordance with the previous reports , patients with p53‐positive and HIF‐1 α ‐positive gastric cancer have worse prognosis, compared with those with double negative cancers.…”

Section: Discussionsupporting

confidence: 86%

“…As our study was limited to the protein level of E-cadherin expression, further analysis at gene levels and epigenetic level may help reveal the molecular pathogenesis mechanisms for E-cadherin in a large sample Chinese EOGC cases [28]. p53 is one of the most important genes that are mutated in gastric cancer [29,30]. In accordance with the previous reports [31], patients with p53-positive and HIF-1α-positive gastric cancer have worse prognosis, compared with those with double negative cancers.…”

Section: Discussionmentioning

confidence: 99%

Expression profile of E‐cadherin, estrogen receptors, and P53 in early‐onset gastric cancers

Zhang

Shi

et al. 2016

Cancer Medicine

View full text Add to dashboard Cite

Early‐onset gastric cancer (EOGC) is predominant in females, diffuse histology, and hereditary pattern. Germline mutation of CDH1 and p53 has been reported previously and female dominance was speculated to be associated with estrogen and its receptors. Expression of E‐cadherin, estrogen receptor α (ER α), estrogen receptor β (ER β), and p53 in EOGC remains unclear, which was the focus of this study, to assess clinical significance of their expression in EOGC. The expression of E‐cadherin, ER α, ER β, and p53 in tumors and normal tissues from surgically resected EOGCs was assessed by immunohistochemistry (n = 139) and Western blot (n = 7) methods, respectively. The expression in tumor tissues was significantly higher for ER α, ER β, and p53, but lower for E‐cadherin, compared to uninvolved mucosa. Positive staining of ER β and p53 was more frequently observed in younger patients with advanced TNM stages. For E‐cadherin, significant correlation was observed between the immunopositivity and TNM stages IA+IB. P53‐negative patients had significantly better outcomes than p53‐positive patients. Significant association between expression of E‐cadherin and histologic types was found in familial, but not in sporadic, EOGC. In conclusion, our results demonstrated E‐cadherin may have a role in initiation of EOGC and positive ER β and p53 expression may partially explained early‐onset and tumor progression of EOGC.

show abstract

“…The results also indicated that the mutant p53 positive rate was higher in OSCC patients with lymph node metastasis than those without metastasis (33), suggesting that neck dissection should be performed for OSCC patients with expression of mutant p53. Mutant p53 positive rate in later clinical phases is higher than that in the early clinical phase (34), suggesting that mutant p53 promotes the development of OSCC. Overall, expression of mutant p53 is associated with the occurrence and development of OSCC, and contributes to the effective design of OSCC treatment programs.…”

Section: Discussionmentioning

confidence: 94%

Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy

Zhang

2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the correlation between the positive expression rate of mutant p53 and the clinical characteristics of patients with oral squamous cell carcinoma (OSCC), as well as the effectiveness of intra-arterial chemotherapy. Expression of mutant p53 in tumor tissues was determined by immunohistochemical analysis of 51 OSCC patients, prior to and following intra-arterial chemotherapy. Prior to intra-arterial chemotherapy, mutant p53 positive rates in patients with higher pathological grades were significantly higher than those of the patients with lower pathological grades. The mutant p53 positive rate in patients with lymph node metastasis was 73% (19/26), which was significantly higher than that of the patients without lymph node metastasis (20%, 5/25). Mutant p53 was expressed in 17% (3/18) of clinical phase II patients, while 64% (21/33) of clinical phase III and IV patients exhibited positive expression of mutant p53 (P<0.05). The mutant p53 positive rate in chemotherapy non-responsive patients was 69% (11/16), which was significantly higher than that in the chemotherapy-responsive patients (37%, 13/35). Mutant p53 positive rates were not significantly correlated with age, gender or the location of the tumor. The mutant p53 positive rate prior to chemotherapy was 47% (24/51), and decreased to 18% (9/51) following chemotherapy. Expression of mutant p53 was decreased in all 13 (100%) chemotherapy-responsive patients, while only 5 (45%) chemotherapy non-responsive patients exhibited reduced expression levels of mutant p53 (P<0.05). In conclusion, mutant p53 has a significant role in the differentiation, development and treatment guidance of OSCC. Intra-arterial chemotherapy with 5-fluorourcil and carboplatin potentially exerts a therapeutic effect by reducing the expression of mutant p53.

show abstract

Clinicopathological and p53 Gene Alteration Comparison between Young and Older Patients with Gastric Cancer

Cited by 16 publications

References 33 publications

Gastric Carcinomas in Young (Younger than 40 Years) Chinese Patients

Gastric Carcinomas in Young (Younger than 40 Years) Chinese Patients

Expression profile of E‐cadherin, estrogen receptors, and P53 in early‐onset gastric cancers

Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy

Contact Info

Product

Resources

About